Haleon Leverages GLP-1 Side Effects for Retail Growth
Haleon, a London-listed consumer health company behind brands like Advil and TUMS, is capitalizing on the side effects of popular GLP-1 weight-loss drugs by strategically placing its products in dedicated retail shelves at CVS Pharmacy. The strategy aims to address common adverse reactions such as nausea, dry mouth, and stomach cramps associated with these medications from Novo Nordisk (NVO) and Eli Lilly (LLY). Early results show a 24% average sales lift per store during the first quarter of 2026. The GLP-1 market is growing rapidly, with around 29 million Americans currently using such drugs. Haleon has exclusive shelf space at CVS for its products and plans to expand this strategy to other major retailers like Walmart and Target if successful. The company's stock performance remains mixed, down slightly over the past month but maintaining a strong portfolio share in most markets.
Topics: CVS GLP-1 drugs Haleon retail partnerships side effects management